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In spite of its many other benefits, DNA vaccine is limited in its application by its insufficient immunoge-
nicity. One promising approach for enhancing its immunogenicity is to maximize its expression in the
immunized host. In the current study, we investigated whether codon optimization of the mycobacterial antigen
Ag85B gene could enhance the expression and immunogenicity of the Ag85B DNA vaccine. We generated a
synthetic humanized Ag85B (hAg85B) gene in which codon usage was optimized for expression in human cells.
DNA plasmids with codon-optimized hAg85B increased the level of protein expression in vitro and in vivo. DNA
vaccine with hAg85B induced stronger Th1-like and cytotoxic T-cell immune responses in BALB/c mice and
generated higher protective immunity in a BALB/c mouse model ofMycobacterium tuberculosis aerosol infection
than did the DNA vaccine with wild-type Ag85B. Therefore, our results suggest that codon optimization of
mycobacterial antigens (e.g., Ag85B) could improve protein expression and thereby enhance the immunoge-
nicity of DNA vaccines against M. tuberculosis.
Tuberculosis is one of the most lethal infectious diseases in
the world, killing two million adults each year (26). Though
childhood immunization with Mycobacterium bovis (BCG) has
likely reduced several severe childhood diseases (e.g., tubercu-
lous meningitis), its efficacy against adult pulmonary disease is
highly variable, with efficacy estimates ranging from 0% to
approximately 80%. Since adult pulmonary disease is the main
threat posed to public health by tuberculosis (14), an improved
vaccine against tuberculosis is urgently needed.
Plasmid DNA encoding antigen Ag85B, one of the Myco-
bacterium tuberculosis secretory antigens, induced cellular im-
mune responses dominated by antigen-specific Th1-type T
cells, thereby affording some protection against subsequent
challenge with M. tuberculosis in mice (25, 43). Although the
immunogenicity of the DNA vaccine encoding Ag85B in mice
was promising, the protective immunity against M. tuberculosis
H37Rv was relatively weak compared to that provided by M.
bovis BCG (25, 30).
Though DNA vaccines offer many benefits, their usefulness
is limited by their insufficient immunogenicity (2, 40, 49). Var-
ious attempts have been made to improve DNA vaccines, in-
cluding coexpression of cytokines (3, 19) or chemokines (13),
modification of subcellular localization of expressed antigen
(Ag) (29, 38), induction of apoptosis (39) or antiapoptosis (27)
of transfected cells, the targeting of Ag to the major histocom-
patibility complex class I or II processing pathway (37), and the
use of self-destructing attenuated intracellular bacteria as car-
riers for the DNA vaccines (31).
One promising approach for improving the response of na-
ked DNA vaccine is to maximize its expression in mammalian
cells (15, 38). Recently, several reports showed that codon
optimization or codon usage modification of genes encoding
human papillomavirus E7 (7), human immunodeficiency virus
gp120 (1, 21), gp160 (48), Gag (8), Plasmodium falciparum
EBA-175 (36), Clostridium tetani TetC (44), and Listeria mono-
cytogenes LLO91-99 (34, 47) toward human consensus codon
usage significantly increased both the protein expression and
the immunogenicity of DNA vaccines.
In the current study, we have attempted to investigate
whether codon optimization of the Ag85B gene could enhance
the expression and the immunogenicity of the Ag85B DNA
vaccine. Although “optimized codons” for protein synthesis
may be different defending on species, most mammals includ-
ing Homo sapiens and Mus musculus have very similar codon
usage (35). Therefore, we tested the efficacy of DNA vaccine
with humanized codon usage in mice. To this end, we gener-
ated a synthetic humanized Ag85B (hAg85B) gene in which
codon usage was optimized for expression in human cells.
DNA vaccine with codon-optimized Ag85B induced higher
immune responses and stronger protective immunity in a
BALB/c mouse model of M. tuberculosis infection than did a
vaccine with wild-type Ag85B, suggesting that the efficacy of
DNA vaccines against M. tuberculosis can be significantly im-
proved by codon optimization.
MATERIALS AND METHODS
Plasmid constructions. To generate the pCK-Ag85B (pAg85B), Ag85B cDNA
was cloned from the genomic DNA of M. tuberculosis H37Rv by using the
upstream primer 5-GAA TTC GCC GCC ACC ATG ACA GAC GTG AGC
CGA AAG-3 and the downstream primer 5-GCG GCC GCT CAG CCG GCG
CCT AAC GAA CTC TG-3 (restriction sites are underlined). The hAg85B
cDNA was synthesized by assembling mutually priming synthetic oligonucleo-
tides (Fig. 1). The gene was divided into nine segments of approximately equal
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cykang@snu.ac.kr.
5666
 o
n
 July 1, 2014 by YO
NSEI UNIV M
ED LIBRARY
http://iai.asm
.org/
D
ow
nloaded from
 
length, and nine pairs of oligonucleotides were synthesized; each pair consisted
of two overlapping long oligonucleotides with a short stretch of overlap contain-
ing restriction endonuclease recognition sites (Fig. 1, underlined residues), with
one oligonucleotide coding for the sense strand and the other coding for the
antisense strand. Some deviations from strict adherence to optimized codon
usage were made to accommodate the introduction of unique restriction sites
into the final gene product at approximately 150-bp intervals (Fig. 1). Each gene
segment was amplified by PCR and ligated to a pGEM-T vector (Promega). The
correct sequence was confirmed by DNA sequencing (3730 DNA Analyzer;
Applied Biosystems). The final product was amplified by PCR, using a pair of
oligonucleotides partially complementary to hAg85B cDNA (boldfaced in the
sequences presented below) and containing restriction sites EcoRI and NotI
(underlined in the sequences presented below) for cloning. The sequence of the
upstream primer, which includes a Kozak consensus sequence, was 5-GAA TTC
GCC GCC ACC ATG ACC GAC GTG TCC CGC AAG-3, and the sequence of
the downstream primer was 5-GCG GCC GCT CAG CCG GCG CCC AGG
CTG GAC TGC AGG TC-3. The resulting hAg85B gene was cloned into pCK
(3, 6, 28). The plasmids were electroporated into Escherichia coli Top10F
and purified from large-scale cultures using a QIAGEN Endofree Giga Kit
(QIAGEN, Hilden, Germany).
Analysis of codon usage. The most commonly used codons for H. sapiens
and M. tuberculosis were determined using the Codon Usage Database on the
GenBank website (www.kazusa.or.jp/codon/).
Mice and immunization. Female BALB/c mice (Charles River, Biogenomics,
Seoul, Republic of Korea) were kept at 22°C and 55% relative humidity on a 12-h
day-night rhythm and given free access to food and water. The mice were housed
in germ-free conditions at the Laboratory Animal Center of Seoul National
University until use. Mice used in the studies were from 6 to 8 weeks of age. Prior
to experimental manipulation, mice were anesthetized with an intraperitoneal
injection of ketamine-xylazine. Each of the BALB/c mice was twice intramuscu-
larly injected, at 2-week intervals, in the right and left tibialis anterior muscles
with 100 g of plasmid DNA in 100 l of phosphate-buffered saline (PBS) using
a 30-gauge insulin syringe. The negative control group was injected with the same
volume (100 g/mouse) of an empty pCK vector.
For protection assays, specific pathogen-free 6-week-old female BALB/c mice
were purchased from Japan SLC, Inc. (Shijuoka, Japan), maintained under
barrier conditions in a BL-3 biohazard animal room at Yonsei University Med-
ical Research Center, and fed a sterile commercial mouse diet and water ad
libitum. All experiments were done in compliance with relevant laws and insti-
tutional guidelines.
FIG. 1. Nucleotide sequences of the Ag85B cDNA and the deduced amino acid sequences. Above each codon is the single-letter designation
for the amino acid. The humanized codons introduced in the hAg85B sequence are shown below the substituted nucleotide of Ag85B. The sites
of the restriction enzymes used to assemble extended pairs of oligonucleotides are underlined and in boldface.
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Peptides. The sequence of the p11 peptide used in the assays is LTSELPQW
LSANRAVKPTGS (amino acids 141 to160) from Ag85B (GenBank accession
no. AAO62005). p11 was an H2d-restricted Th1 T-cell epitope peptide of Ag85B,
which was known to induce the production of interleukin-2 (IL-2) and gamma
interferon (IFN-) in response to restimulation of spleen cells from BALB/c
mice vaccinated with plasmid DNA encoding Ag85B or infected with M. tuber-
culosis (12).
In vitro transfection studies and Western blotting. COS-7 cells were tran-
siently transfected with plasmids by Effectene (QIAGEN), and cells were har-
vested 48 h posttransfection. Total cell lysates were prepared by using Cyto-
Buster Protein Extraction Reagent (Novagen), which was supplemented with a
complete protease inhibitor cocktail (Roche). Equal amounts of cell lysates (400
g of total protein) were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and then transferred onto nitrocellulose membranes (BioTrace
NT; Pall Corporation, Ann Arbor, MI). Blots were blocked for 1 h at room
temperature in PBS containing 5% nonfat dried milk and 0.1% Tween 20 under
gentle shaking. Membranes were incubated overnight with Ag85B-specific poly-
clonal antibody that was purified from sera of BALB/c mice immunized with
recombinant Ag85B protein and adjuvants. Then, membranes were incubated
with a 1:2,000 dilution of horseradish peroxidase-conjugated goat anti-mouse
immunoglobulin G (IgG; Sigma, St. Louis, MO). The liquid diaminobenzidine
substrate-chromogen system (DakoCytomation, Fort Collins, CO) was used for
Western blotting. The intensity of each band was read by using a ChemiImager
4400 densitometer (Alpha Innotech, San Leandro, Calif.) and calculated by
AlphaEase version 5.5 software.
Luciferase assay. The pAg85B- and phAg85B-luciferase plasmids were con-
structed by using the luciferase gene of the pGL3-Enhancer (Promega, Madison,
WI), and luciferase activity was measured in duplicate using a Dual Luciferase
Assay kit (Promega), following the manufacturer’s recommendations, along with
a Luminoskan Ascent luminometer (Thermo Labsystems USA, Franklin, MA).
Luciferase activity was normalized by -galactosidase activity. For the in vivo
expression assay, 200 g of luciferase-expressing plasmids was intramuscularly
injected into the right tibialis anterior muscle of BALB/c mice. Fourteen days
later, muscles around the site of injection were removed and homogenized. After
lysis, 20 l of cell lysates (0.5 mg/ml) was added into each well, along with 100 l
of the luciferin buffer. Light emission was registered immediately in the lumi-
nometer as relative light units (RLU) (20-s integration and 1-s settle time).
RT-PCR. To assess the mRNA transcription level in the cells transfected with
plasmids, the constructed plasmid was transfected into CT26 cells and COS-7
cells as described above, and after 48 h, total RNA was isolated using an RNeasy
mini kit (QIAGEN), as directed in the user’s manual. For digestion of the DNA
plasmid, DNaseI (RNase-free) (Takara, Shiga, Japan) was treated following the
manufacturer’s protocol. For reverse transcription PCR (RT-PCR), 2.5 g of
total RNA was reverse transcribed into cDNA by oligo(dT) priming using su-
perscript II RT (Invitrogen Life Technologies, Carlsbad, CA) according to the
manufacturer’s instructions. Sense and antisense primers used in the PCR were
as follows: for Ag85B, 5-CAG CAG TTC ATC TAC GCC-3 and 5-GAA GTT
GAA CAC GGC GTT GTG-3; for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), 5-TTA GCA CCC CTG GCC AAG G-3 and 5-CTT ACT CCT
TGG AGG CCA TG-3. Equal aliquots of RT-PCR product for Ag85B (348 bp)
and GAPDH (500 bp) were separated on 1.5% agarose gels and stained with
ethidium bromide. Agarose gels were scanned by densitometer to measure the
densities of bands. The ratio of Ag85B to GAPDH was calculated and used to
obtain the ratio of Ag85B transcripts (Ag85B:hAg85B).
Enzyme-linked immunosorbent assay (ELISA) for Ag85B-specific Ab. To ob-
tain recombinant Ag85B protein, Ag85B cDNA was cloned into pET28a()
(Novagen, Darmstadt, Germany) and expressed in E. coli BL21(DE3). Recom-
binant Ag85B protein was further purified by Ni-nitrilotriacetic acid agarose
(QIAGEN, Valencia, CA) following the manufacturer’s protocol. Sera from
immunized mice were collected by orbital bleeding 3 weeks after the final
immunization. Alkaline phosphatase-conjugated goat anti-mouse IgG (Pierce,
Illinois), IgG1, or IgG2a antibody (Ab) (Southern Biotechnology, Alabama) was
used to detect Ag85B-specific Ab. The titer of the sera was determined by using
the reciprocal of the last dilution yielding an absorbance twice above the back-
ground, which had been established using saline-injected mouse serum diluted
1:200.
Splenocyte proliferation assay. Splenocytes were prepared from spleens of
immunized mice and erythrocytes were depleted. Cells were plated at 5  105
spleen cells per well in 96-well round-bottom microtiter plates (Nunc) with
complete culture medium. Cells were cultured for 3 days with 10 g/ml of p11 or
alone. After 72 h of incubation, including a final 22-h pulse with [3H]thymidine
(1 Ci per well), the cultured splenocytes were harvested using an automatic
harvester (Skatron, Sterling, VA), and incorporation of the label was measured
using a liquid scintillation counter (Wallac, Turku, Finland).
ELISA for IFN-. Immunized mice were sacrificed 2 weeks after the last
immunization, and spleens were removed aseptically. Spleen cells were plated at
8 106 cells per well and cultured for 72 h in the presence of 10 g/ml of peptide
p11 of Ag85B or alone. Culture supernatants were tested for the presence of
IFN- by sandwich ELISA. For IFN- sandwich ELISA, we used purified rat
anti-mouse IFN- monoclonal Ab (clone R4-6A2), biotinylated rat anti-mouse
IFN- monoclonal Ab (clone XMG1.2) (both from BD Pharmingen, San Diego,
CA), and recombinant IFN-.
ELISPOT assay. The enzyme-linked immunospot (ELISPOT) assay (32) was
modified to detect Ag85B-p11-specific IFN--secreting cells. Briefly, 96-well
multiscreen filter plates (Mutiscreen MAHA; Millipore, France) were coated
with 10 g/ml rat anti-mouse IFN- antibody (clone R4-6A2; BD PharMingen,
San Diego, CA) in 50 l of PBS. After overnight incubation at 4°C, the wells
were washed and blocked for 2 h with 200 l of RPMI medium–10% fetal bovine
serum (FBS; all from Bio Whittaker, MD). Splenocytes were resuspended to 2 
107 cells/ml, placed in duplicates, and serially diluted (1  107, 0.5  107, and
0.25 107 cells/well). Cells were incubated at 37°C for 24 h either with or without
1 g/ml peptide p11. After culture, the plate was washed six times with PBS
containing 1% Tween 20 and then incubated 2 h at room temperature with 5
g/ml biotinylated rat anti-mouse IFN- antibody (clone XMG1.2; BD Phar-
Mingen, San Diego, CA) in 50 l of PBS–10% FBS. After six washes with PBS,
1.25 g/ml peroxidase (Sigma) in 50 l of PBS–10% FBS was added and incu-
bated 1 h at room temperature. Spots were developed by adding 50 l of a
5-bromo-4-chloro-3,3-indolyl phosphate–nitroblue tetrazolium solution (Boehr-
inger Mannhem, Indianapolis, IN) and incubated at room temperature for 10
min. Spots were counted electronically using a Zeiss KS-ELISPOT, version
4.5.21.
51Cr release assay. To prepare the target cell line (CT26-Ag85B) for cytotoxic
assay, mycobacterial Ag85B cDNA was cloned into the mammalian expression
vector pDON-AI (kindly provided by S. Y. Kim, Seoul National University,
Republic of Korea) and cotransfected into the CT26 cell line with pGagPol and
pEnv plasmids (kindly provided by S. Y. Kim, Seoul National University, Re-
public of Korea). Two weeks after the third injection, spleen cells from immu-
nized mice were prepared and restimulated by coculturing with CT26-Ag85B
cells (1  107 cells per mouse) that had been treated with mitomycin C at 37°C
for 30 min. After 6 days of culture, restimulated cells were harvested and used as
effector cells in a 4-h 51Cr release assay. 51Cr-labeled 1 104 CT26-Ag85B target
cells were added to the effector cells. After incubation, a 100-l aliquot was
removed from each well for counting in a Wallac 1470 Wizard automatic gamma
counter. The values were expressed as the percentage of specific lysis. Percent
specific lysis was calculated as [(experimental release  background release)/
(maximal release  background release)]  100. Background release was de-
fined as 51Cr release by target cells in the absence of effector cells, and the
maximal release was determined after lysing target cells with 1% Triton X-100.
Protection assay. Mice were immunized intramuscularly three times at 3-week
intervals with 100 g of pAg85B, phAg85B, or mock vector. In addition, one
group of mice was immunized with BCG (1  105 CFU) twice at weeks 3 and 6.
Four weeks after final immunization, mice were exposed to 500 CFU of M.
tuberculosis H37Rv (ATCC 27294) via aerosol for 60 min in the inhalation
chamber of an airborne infection apparatus (Glas-Col, Terre Haute, Ind.). After
4 weeks, mice were euthanized with CO2, and lungs were homogenized in 0.04%
Tween 80 and saline. The tissue suspension was diluted 10-fold, and 100 l of
each dilution was plated in duplicate onto Middlebrook 7H11 agar plates and
incubated at 37°C for 3 to 4 weeks. M. tuberculosis colonies on each plate were
counted, and the results are expressed as the log10 of CFU per organ. Data are
expressed as the means of individual determinants, plus or minus standard
deviations.
Statistical analysis. The values of P for the experiments were determined
using a Student’s t test and the SigmaPlot 5.0 program (SPSS Inc.).
RESULTS
Construction of an hAg85B gene based on optimal codon
usage. In order to test the hypothesis that codon optimization
would improve the protein expression and the immunogenicity
of Ag85B DNA plasmid (pAg85B), we constructed an hAg85B
DNA plasmid (phAg85B) using the codons which most fre-
quently appear in humans, without altering amino acid se-
quences of pAg85B-encoded protein (Fig. 1). The synthetic
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hAg85B gene was inserted into the mammalian cDNA expres-
sion vector pCK under the control of the human cytomegalo-
virus (HCMV) immediate-early (IE) enhancer and promoter.
pCK contains not only the full-length IE promoter of HCMV
but also its entire 5 untranslated region consisting of the
entire exon 1 and intron a and of a part of exon 2 (28).
Furthermore, the Kozak consensus sequence, GCCGCCACC,
was introduced immediately preceding the insertion of the
AUG initiator codon, which was intended to coincide with the
ATG codon of the original IE gene of HCMV.
Enhanced expression of Ag85B by codon optimization. We
first checked whether the codon optimization of Ag85B could
improve protein expression. To evaluate the relative potency
of the wild-type and humanized Ag85B genes, we compared
Ag85B protein expression by in vitro and in vivo transfection of
the DNA plasmids, pAg85B and phAg85B. At first, the protein
levels expressed by transfection of COS-7 cells with DNA vac-
cine plasmid pAg85B, phAg85B, or mock vector as a negative
control were determined by Western blotting (Fig. 2A). Codon
optimization of Ag85B increased the level of protein expres-
sion approximately sixfold over that of wild-type Ag85B as the
intensity of each band having a molecular mass of 30 kDa
was measured by using densitometer. In the lane of phAg85B-
transfected COS-7 cells, there were two major bands around 30
kDa. We compared the bands of high molecular mass, al-
though we assumed that the lower-molecular-mass band might
be a truncated form of Ag85B.
The protein expression level was also assessed by luciferase
assay. We constructed pCK-Ag85B-luciferase (pAg85B-Luc)
and codon-substituted pCK-hAg85B-luciferase (phAg85B-
Luc) fusion genes and transiently transfected them into COS-7
and CT26 cells. The relative luciferase activities of phAg85B-
Luc were higher than those of pAg85B-Luc in both COS-7 cells
(Fig. 2C) and CT-26 cells (data not shown). Furthermore, we
analyzed the in vivo expression of pAg85B-Luc and phAg85B-
Luc in the muscle cells of mice. For in vivo expression, 200 g
of luciferase-expressing plasmids was intramuscularly injected,
and then 14 days later RLU were determined from the muscle
tissue of the injected site. Injection of phAg85B-Luc resulted
in greater luciferase activity than did pAg85B-Luc (Fig. 2D).
To test whether increased Ag85B mRNA transcripts en-
hanced protein expression levels of phAg85B, we checked the
levels of mRNA expression by pAg85B and phAg85B. At 48 h
posttransfection of CT26 and COS-7 cells with DNA plasmids,
total RNAs were prepared, and Ag85B mRNA levels were
assessed by RT-PCR. The densities of bands on the agarose
gels were measured by a densitometer. The ratio of each
Ag85B transcript to GAPDH was calculated and used to ob-
tain the transcriptional ratio of Ag85B to hAg85B. It was 1:0.93
in CT26 cells and 1:1.02 in COS-7 cells. Therefore, enhanced
protein expression of the hAg85B gene can be ascribed to
increased Ag85B mRNA translation rather than to increased
Ag85B gene transcription (Fig. 2B).
Effects of codon-optimized DNA vaccine on humoral im-
mune responses. Next, we analyzed Ag85B-specific Ab produc-
tion by DNA vaccines. Although the level of IgG produced by
pAg85B or phAg85B immunization was a bit low, it was sig-
nificantly increased compared with that of the mock vector-
injected group (Table 1). However, DNA immunization of
BALB/c mice with codon-optimized phAg85B did not enhance
Ag85B-specific IgG Ab responses quantitatively compared
with those immunized with pAg85B. On the other hand, the
IgG2a/IgG1 ratio showed indirectly that the immune response
by phAg85B was slightly skewed toward Th1 responses.
phAg85B immunization enhanced T-cell activation. Next,
we explored whether immunization with pAg85B or codon-
optimized phAg85B would induce cellular immune responses
against Ag85B in BALB/c mice. As shown in Fig. 3, T-cell
proliferative responses to the Th1 T-cell epitope peptide p11
were only weakly enhanced (2,938 	 1,811 cpm) after DNA
FIG. 2. Increased expression of Ag85B by codon optimization.
(A) Comparative Ag85B expression in COS-7 cells transfected with
pAg85B (lane 1) and phAg85B (lane 2) constructs. As a control,
COS-7 cells were transfected with mock plasmid (lane 3). Cell lysates
(400 g of total protein) were separated by sodium dodecyl sulfate–
10% polyacrylamide gel electrophoresis and analyzed by immunoblot-
ting with Ag85B-specific polyclonal antibody. The arrow at the right
indicates the position of the Ag85B protein. The sizes of protein
standards (lane M) are indicated in kilodaltons (kDa) at the left.
(B) Total RNA was extracted and analyzed for relative levels of Ag85B
mRNA by RT-PCR. Agarose gels were scanned by densitometer to
measure the densities of bands. The ratio of Ag85B to GAPDH was
calculated and used to obtain the ratio of Ag85B transcripts (Ag85B:
hAg85B). Data are representative of at least two independent exper-
iments. (C) Comparison of translational efficacy of pAg85B-Luc and
phAg85B-Luc. COS-7 cells were transiently transfected with each plas-
mid, and 48 h after the transfection, cells were lysed, and luciferase
activities were assayed. Data represent relative luciferase activities,
with transfection efficiencies normalized by -galactosidase activity.
One representative of at least three performed experiments is shown.
, P 
 0.03. (D) For the in vivo expression assay, 200 g of luciferase-
expressing plasmids was intramuscularly injected into the right tibialis
anterior muscle of BALB/c mice (2 mice per group), and RLU were
determined 14 days later. Data are representative of at least three
independent experiments.
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immunization with pAg85B but increased fivefold (13,377 	
921 cpm) after DNA immunization with phAg85B. Similarly,
splenocyte proliferative responses toward purified recombi-
nant Ag85B or culture filtrate protein were also increased by
codon optimization (data not shown).
Since the CpG content of phAg85B was slightly changed
after codon optimization, we addressed whether the change in
CpG contents would affect T-cell activation.
To compensate for the differences in the CpG contents of
pAg85B and phAg85B sequences, mice were immunized intra-
muscularly with 100 g (each) of pAg85B and pGEM-T-
hAg85B (pAg85BphA) or phAg85B and pGEM-T-Ag85B
(phAg85BpA). Since the pGEM-T vector was unable to be
expressed in mammalian cells, pGEM-T-Ag85B (pA) and
pGEM-T-hAg85B (phA) were coadministered with phAg85B
and pAg85B, respectively, to control for differences in the CpG
contents between the two genes. Immunization with
phAg85BpA increased antigen-specific proliferation signifi-
cantly more than did pAg85BphA immunization, demon-
strating that the difference in immunogenicity was not the
consequence of differences in CpG content (Fig. 3). Collec-
tively, these results indicate that DNA immunization of
BALB/c mice with codon-optimized phAg85B increases the
Ag85B-specific T-cell proliferative responses significantly
more than does pAg85B, regardless of differences in the CpG
contents of DNA vaccines.
phAg85B DNA immunization enhances IFN- expression.
The IFN- production of pAg85B-immunized and phAg85B-
immunized spleen cells was measured using ELISA and
ELISPOT assays. As shown in Fig. 4A, the phAg85B-immu-
nized spleen cells (16,481 	 2,260 pg/ml) produced much
higher levels of IFN- than did pAg85B-immunized spleno-
cytes (6,783 	 1,893 pg/ml). IFN- was hardly detected in the
culture supernatants of spleen cells taken from mice immu-
nized with a mock vector (Fig. 4A). Consistent with this ob-
servation, the number of antigen-specific IFN--secreting cells
detected in splenocytes from mice immunized with phAg85B
FIG. 3. Increased proliferative responses after phAg85B immuni-
zation. Proliferative responses of spleen-derived lymphocytes from
five mice immunized intramuscularly twice at 2-week intervals with
100 g of pAg85B, phAg85B, or the mock vector. To compensate
for the difference in CpG contents between the pAg85B and phAg85B
sequences, a combination of 100 g (each) of pAg85B and pGEM-T-
hAg85B (pAg85BphA) or phAg85B and pGEM-T-Ag85B (phAg85B
pA) was injected. Two weeks after the final immunization, the incor-
poration of [3H]thymidine in response to 10 g/ml p11 was measured
as described in Materials and Methods. Spleens were from five mice
tested individually, and results are expressed as the means 	 standard
errors (cpm). The statistical significance of the difference in the pro-
liferative response was determined by a Student’s t test. , P
 0.05; ,
P 
 0.001.
FIG. 4. phAg85B immunization increased IFN- secretion.
(A) IFN- secreted by p11 peptide-stimulated spleen cells from
pAg85B-immunized or phAg85B-immunized mice. BALB/c mice were
immunized intramuscularly with pAg85B, phAg85B, or mock vector
twice at 2-week intervals. Spleen cells from immunized mice were
harvested 2 weeks after the last immunization and stimulated by cul-
turing in the presence or absence of 10 g/ml of p11 peptide for 3 days.
The concentration of IFN- in the culture supernatants was deter-
mined by sandwich ELISA. Splenocytes from mice immunized with a
mock vector were used as negative control. Results are expressed as
the mean 	 standard error. A statistically significant difference was
observed in levels of IFN- secreted by spleen cells immunized with
pAg85B and those with phAg85B. , P
 0.03. (B) ELISPOT estimates
of the frequencies of cells that produced IFN- in response to 10 g/ml
p11 peptide for 24 h. The results are expressed as the mean	 standard
error of spot-forming cells (SFC) per 106 splenocytes. There was a
remarkable difference in the levels of IFN--secreting cells detected in
the groups immunized with pAg85B and those with phAg85B. , P 

0.01.
TABLE 1. Effect of phAg85B immunization on humoral responses against Ag85B
Immunizationa
Log2 ELISA titerb
IgG2a/IgG1 ratio
Total IgG IgG1 IgG2a
pAg85B 10.64 	 0.38c 11.64 	 0.53c 12.50 	 0.34c 2.64 	 0.99
phAg85B 10.52 	 0.58c 10.48 	 0.79c 12.48 	 0.83c 4.67 	 1.16
Mock vector 6.27 	 0.18 
5.64 6.93 	 0.29
a Mice were immunized with 100 g of pAg85B or phAg85B intramuscularly three times at 3-week intervals. The titers of Ag85B-specific IgG, IgG1, and IgG2a
antibodies were determined by ELISA with sera recovered 2 weeks after the final immunization, and the ratios of IgG2a to IgG1 were calculated.
b The results are log2(titer 	 SE) of endpoint titers for six to eight mice per group.
c P 
 0.005 versus mock vector injected group.
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was twice (P
 0.01) that observed in pAg85B-immunized mice
(Fig. 4B). Therefore, immunization with phAg85B increased
antigen-specific IFN- secretion of Th1 cells.
We also used a sandwich ELISA to measure the IL-4 pro-
duction of splenocytes from immunized BALB/c mice. How-
ever, IL-4 production was not detected in any of the mice
examined (data not shown).
Immunization with phAg85B DNA increased CTL activities.
We examined how DNA immunization using the codon-opti-
mized Ag85B gene affected the induction of specific cytotoxic
T lymphocytes. As shown in Fig. 5A, splenocytes from BALB/c
mice immunized twice at 2-week intervals with phAg85B more
strongly lysed CT26-Ag85B cells than did pAg85B-immunized
splenocytes after in vitro restimulation by the CT26-Ag85B
cells treated with mitomycin C for 6 days. In contrast, neither
pAg85B nor phAg85B immunization induced the specific lysis
of CT26 cells (Fig. 5B).
In order to assess the influence of the CpG motif on the high
CTL activity of phAg85B-immunized mice, groups of BALB/c
mice were first immunized with pAg85BphA or
phAg85BpA and then tested for CTL responses. In these
experiments, the specific lysis of phAg85BpA-immunized
mice was 85.65% 	 11.17% and that of pAg85BphA-immu-
nized mice was 48.24% 	 2.50% at an effector/target ratio of
30 (Fig. 5C). These data strongly indicate that the differences
in the CpG contents of pAg85B and phAg85B sequences did
not significantly contribute to the capacity of phAg85B to in-
duce higher Ag85B-specific CTL responses.
DNA immunization with phAg85B enhances protective effi-
cacy. Finally, we investigated whether optimizing the codon
usage of the Ag85B DNA vaccine would enhance its protective
efficacy against airborne M. tuberculosis H37Rv infection in the
BALB/c mouse model. Mice were immunized intramuscularly
three times at 3-week intervals with 100 g of pAg85B,
phAg85B, or mock vector. Four weeks after the final immuni-
zation, mice were exposed to 500 CFU of M. tuberculosis
H37Rv via aerosol for 60 min, and bacterial numbers in organs
were determined 4 weeks after infection. DNA immunization
with phAg85B provided a significant level of protection against
M. tuberculosis, compared with mock immunization, in both
lungs and spleens, where protections were comparable to that
afforded by BCG (Fig. 6). In contrast, the protective efficacy of
pAg85B immunization in the lungs was variable, and the pro-
tection by pAg85B immunization was not significant compared
to immunization with mock vector alone (Fig. 6). Interestingly,
immunization with phAg85B achieved a more consistent and
significant level of protection against M. tuberculosis infection
in the lungs than did pAg85B immunization (P
 0.05) (Fig. 6).
In addition, the number of CFU in spleens of phAg85B-im-
munized mice was lower than that seen in mice injected with
pAg85B (Fig. 6), although there was no significant difference in
CFU (P  0.065). These results demonstrate that codon-opti-
mized pAg85B induced a higher degree of protective immunity
in a BALB/c mouse model of M. tuberculosis aerosol infection
than did wild-type Ag85B. In particular, the enhanced protec-
tion in the primary infection site, the lungs, is meaningful.
DISCUSSION
Although vaccination with plasmid DNA encoding mycobac-
terial Ag85B has been shown to induce protective immunity
against M. tuberculosis through immune responses mediated by
CD4 Th1 cells and CD8 T cells (9, 23), the extent of pro-
tective efficacy was relatively weak compared to that of M.
FIG. 5. Codon usage effects of DNA vaccine on CTL induction. (A
and B) BALB/c mice were immunized intramuscularly with 100 g of
mock vector, pAg85B, or phAg85B twice at 2-week intervals. (C) To
compensate for the differences in CpG contents of the pAg85B and
phAg85B sequences, mice were injected with a combination of 100 g
each of pAg85B and pGEM-T-hAg85B (pAg85BphA) or with
phAg85B and pGEM-T-Ag85B (phAg85BpA). Spleen cells from
mice immunized with 200 g of mock vector were used as a negative
control. Each of the splenocytes from the immunized mice (5 mice/
group) was harvested 2 weeks after the last immunization and stimu-
lated with mitomycin C-treated CT26-Ag85B cells for 6 days in vitro.
Cytotoxicity of splenocytes was evaluated in a 4-h 51Cr-release assay
against CT26-Ag85B cells (A and C). Nonspecific lysis was evaluated
by using CT26 as target cells (B). The values were expressed as the
mean percentage 	 standard error of specific lysis from individual
mice. The significance of the difference between pAg85B and
phAg85B was calculated by a Student’s t test. , P
 0.03; , P
 0.01.
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bovis BCG (11, 25, 30, 46). Recently, DNA immunization fol-
lowed by boosting with protein vaccine (4) or modified vaccinia
virus Ankara (16) was shown to increase the protective immu-
nity against M. tuberculosis H37Rv challenge to a level com-
parable to that afforded by BCG. However, the efficacy of the
DNA vaccine itself needs to be improved. In the current study,
we showed that DNA immunization with codon-optimized
phAg85B in mice significantly enhanced the Ag85B-specific
Th1-type immune responses and CTL activities and provided
protective immunity against M. tuberculosis.
The relative importance of CD4 Th1 cells and CD8 T
cells in antituberculosis immunity remains a subject of debate
(5, 10, 33). However, Th1 responses seem to be important for
diseases requiring cellular immunity such as Leishmania major,
M. tuberculosis, and malaria (17). In this regard, a recent report
showed that CD8 T cells may have an important role in
maintaining the frequency of CD4 IFN--producing T cells
(18). In addition, another previous study suggested that the
amount of antigen expression by plasmid DNA is important for
efficient T-cell priming (38). In particular, the appropriate
CD4 T-cell immune responses appear to require repeated Ag
exposure and a sufficient amount of Ag (4, 22, 38). Further-
more, CD4 T-cell help is essential for CTL priming and
memory CTL formation (24, 42). Therefore, if the amount of
antigen expressed by a DNA vaccine were increased, the CD4
Th1 cell-mediated immune responses could be enhanced,
thereby also improving CD8 T-cell immunity.
In this study, we constructed an hAg85B DNA vaccine plas-
mid (phAg85B) with human codon usage to improve the ex-
pression of a pAg85B DNA vaccine in mammalian cells. We
used the most prevalent codon in humans as the optimized
codon of the final gene product. In wild-type mycobacterial
Ag85B, many of the Ser and Pro amino acid residues are
encoded by triplets rarely seen in human genes. By substituting
high-usage codons for these low-usage codons without altering
the amino acid sequences, we could increase the level of
Ag85B protein expression approximately sixfold in mammalian
cells. Because the GC content of mycobacterial Ag85B is
very high (64.2%), the GC content was raised to approxi-
mately 68.5% in the optimized sequence. In comparison, the
overall genome GC contents of vertebrates were 52.31% (in
Mus musculus) and 52.59% (in Homo sapiens) (35). Therefore,
we tested whether the high GC content would affect mRNA
transcription in mammalian cells. Interestingly, the enhanced
protein expression of the hAg85B gene was due to the in-
creased Ag85B mRNA translation rather than to the increased
Ag85B gene transcription.
We also investigated whether immune responses elicited by
DNA vaccines could be affected by changes in the nucleotide
composition of DNA sequences such as alterations in CpG
content. It has previously been demonstrated that the codon
optimization of the gp120 gene introduced additional CpG
motifs into the sequence, perhaps thereby increasing immuno-
genicity, as these motifs are known to stimulate innate immu-
nity (1, 21). In contrast, the codon optimization of the human
immunodeficiency virus type 1 gag gene results in increased
immunogenicity due to enhanced gag expression, not to the
accumulation of CpG motifs (8). Furthermore, the codon op-
timization of DNA encoding fragment C of tetanus toxin
(TetC) has been shown to increase anti-TetC antibodies in the
sera of immunized mice, even when the CpG contents of syn-
thetic and native genes were made uniform (44). In our study,
we codelivered a control vector to compensate for the effect of
the increased numbers of CpG motifs in the humanized Ag85B
gene. Even when the impact of the elevated CpG motifs was
thus neutralized, T-cell proliferation and CTL activity re-
mained high, showing that the increase in Ag85B-specific im-
mune responses was not due to the increase in CpG motifs.
Instead, we ascribed the increased immunogenicity of
phAg85B to the increased expression of Ag85B in the host.
However, humoral responses elicited by DNA vaccines were
relatively weak, with no significant differences detected be-
tween mice immunized with pAg85B and phAg85B. Since both
pAg85B and phAg85B lacked a mammalian signal sequence
such as human Ig() signal leader or the tissue plasminogen
activator signal sequence in their transcription units, most of
the Ag85B expressed by the DNA vaccine was not secreted out
of cells. Instead, the enhanced Ag85B expression induced by
codon optimization occurred mainly inside transfected cells
and so did not significantly affect humoral responses. During
FIG. 6. Enhanced protective efficacy after immunization with codon-optimized phAg85B. Protection against M. tuberculosis in mice immunized
intramuscularly three times at 3-week intervals with 100 g of pAg85B, phAg85B, or mock vector. Mice were challenged with 500 CFU of M.
tuberculosis H37Rv by inhalation and bacterial counts in lungs and spleen were determined 4 weeks after infection. Data are the means 	 standard
deviations of three mice. , P 
 0.05; , P 
 0.01.
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apoptosis or cell damage, Ag85B might be released and be-
come available for B cells and dendritic cells. Presumably,
these processes, which are required following protein expres-
sion, could substantially limit the level of humoral responses
induced by DNA vaccines.
Although Ag85B is a promising vaccine candidate, it has
been reported that the production of Ag85B decreased during
chronic infection of M. tuberculosis in the mouse lungs (41). It
has also been reported that the Ag85A epitopes are frequently
expressed on the surface of the infected macrophages during
early phase but are downregulated at the late phase (45).
Because the levels of expression of Ag85B were similar to
those of Ag85A at corresponding times of infection (41), we
just assessed the protective efficacy of Ag85B-specific immune
responses during early phase. For the protection of both early
and late phases of mycobacterial infection, development of a
multigene DNA vaccine composed of hAg85B and a different
antigen which is expressed at least during the late stage of
infection may be needed.
In summary, we demonstrated that the optimization of the
M. tuberculosis Ag85B coding sequences to those of highly
expressed mammalian genes resulted in substantial improve-
ment in protein expression by mammalian cells. In addition,
DNA vaccine with codon-optimized hAg85B induced stronger
Ag85B-specific Th1-like and cytotoxic T-cell immune re-
sponses in BALB/c mice and induced higher protective immu-
nity in a mouse model of M. tuberculosis aerosol infection than
did the DNA vaccine with wild-type Ag85B. Therefore, our
results suggest that the optimization of codon usage of myco-
bacterial antigens could improve protein expression and con-
sequently enhance the immunogenicity of DNA vaccines
against M. tuberculosis. Our approach to improving the immu-
nogenicity of Ag85B DNA vaccine via enhanced antigen ex-
pression included the optimization of codon usage of the my-
cobacterial Ag85B gene. This was the first attempt to assess the
codon optimization of a mycobacterial antigen on protein ex-
pression in the mouse model. Surprisingly, DNA immunization
of BALB/c mice with codon-optimized phAg85B alone in-
duced protective immunity comparable to that afforded by
BCG. Furthermore, the strategy of combining DNA vaccines
of codon-optimized mycobacterial antigens with other promis-
ing approaches could facilitate the design of improved antitu-
berculosis vaccines for clinical applications.
Next, we will construct a bicistronic vector expressing codon-
optimized hAg85B and another mycobacterial antigen such as
PstS-3 or ESAT-6 for preclinical study in mice and nonhuman
primates. Recently, multigene DNA vaccination combined si-
multaneously with chemotherapy was proposed as one of the
efficient strategies for patients undergoing tuberculosis chemo-
therapy to prevent exogenous reinfection as well as endoge-
nous reactivation (20). For the clinical use of this strategy, the
optimization of codon usage of a mycobacterial antigen of a
DNA vaccine may be essential.
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